米国の臨床腫瘍学次世代シーケンス市場規模、シェア、動向分析レポート：ワークフロー別、技術別、用途別、最終用途別、セグメント予測、2023年～2030年

米国の臨床腫瘍学次世代シーケンス市場の成長と動向

Grand View Research, Inc.の最新レポートによると、米国の臨床腫瘍学次世代シーケンス市場は2030年までに5億40万米ドルに達する見込みです。

2023年から2030年までのCAGRは15.1%で市場拡大が見込まれます。同市場は、業界企業間の競争激化、同分野の技術進歩、遺伝子配列決定のコスト低下により、2023年から2030年の予測期間中に大幅な成長が見込まれています。

市場競争の激化と、腫瘍学分野における次世代シーケンサーに基づく革新的ソリューションの発売は、予測期間中の市場成長を促進すると予想されます。例えば、2023年2月、がんスクリーニングおよび診断検査会社であるExact Sciences Corp.は、米国で治療選択検査-OncoExTraを発表しました。これは、がん治療に役立つ次世代シーケンスベースのゲノム検査です。がん腫瘍の理解と特徴づけに役立ちます。さらに、この業界で競争優位に立つために、各社は協力して次世代シーケンシングの進歩に注力しています。例えば、2020年1月、市場で事業を展開する2つの主要企業、Illumina, IncとF. Hoffmann-La Roche Ltdは、がんの検出、診断、リスク予測、治療、モニタリングを変革するNGSの可能性を発見する15年契約を締結しました。

さらに、腫瘍学やがん治療におけるNGSの利用について、さまざまな論文や研究が発表されています。例えば、2023年6月、Lancet誌は、がん患者におけるNGS検査の実臨床結果と有用性に関する論文を発表しました。さらに2023年6月には、米国臨床腫瘍学会（American Society Of Clinical Oncology）が、米国における進行がんの管理におけるNGS検査の臨床的影響に関する調査を発表しました。このような調査は、研究者や臨床医ががん治療におけるNGSの使用に関する認識や知識を高めるのに役立っています。

さらに、予測期間中の臨床腫瘍学次世代シーケンス市場の成長は、シーケンシングコストの削減による成長が見込まれます。NGSのコストは、パラレルシーケンスを増やし、複数のフローセルを稼働させることで、それに関連するコストを上げることなくシーケンス能力を高めることで削減できます。これらの要因によって、米国では予測期間中に市場需要が高まると予測されています。

米国の臨床腫瘍学次世代シーケンス市場レポートハイライト

• ワークフローセグメントに基づく2022年の収益シェアは、NGSシーケンスが55.6%で最大。このセグメントの優位性は、がんシーケンスプロジェクトの増加およびこの分野の技術進歩によるものです。
• 技術別では、ターゲットシーケンス＆リシーケンスが2022年の収益シェア72.9%で市場を独占しました。これは、標的化パネルの使用の増加と、がん腫瘍の同定におけるその効率性に起因します。
• 用途別では、スクリーニング分野が米国の臨床腫瘍学NGS市場を独占し、2022年の収益シェアは80.6%でした。
• 最終用途に基づくと、2022年の米国臨床腫瘍学NGS市場では、検査室セグメントが64.4％の最大シェアを占めました。このセグメントの優位性は、がん治療のための研究開発活動の高まりによるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因分析
• 業界分析ツール
  • SWOT分析;要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 米国の臨床腫瘍学次世代シーケンス市場の分類：技術推定・動向分析

• 米国臨床腫瘍学NGS市場：技術変動分析
• テクノロジー別
• 全ゲノム配列決定
  • 全ゲノムシーケンス市場、2018年から2030年
• 全エクソームシーケンス
  • 全エクソームシーケンシング市場、2018～2030年
• ターゲットシーケンシングとリシーケンシング
  • ターゲットとなるシーケンスおよび再シーケンス市場、2018～2030年

第5章 米国の臨床腫瘍学次世代シーケンス市場の分類：ワークフローの推定・動向分析

• 米国の臨床腫瘍学NGS市場：ワークフロー変動分析
• ワークフロー別
• 5 NGSプレシーケンス
• NGSシーケンス
• NGSデータ分析

第6章 米国の臨床腫瘍学次世代シーケンス市場の分類：用途の推定・動向分析

• 米国臨床腫瘍学NGS市場：用途変動分析
• 最終用途別
• スクリーニング
  • 米国臨床腫瘍学NGS市場のスクリーニング、2018～2030年
  • 散発性がん
  • 遺伝性がん
• コンパニオン診断
  • コンパニオン診断の米国臨床腫瘍学NGS市場、2018～2030年
• その他の診断
  • その他の診断薬の米国臨床腫瘍学NGS市場、2018～2030年

第7章 米国の臨床腫瘍学次世代シーケンス市場の分類：最終用途の推定・動向分析

• 米国の臨床腫瘍学NGS市場：最終用途の変動分析
• 最終用途別
• 病院
• クリニック
• 研究室

第8章 競合情勢

• 企業の分類
• 戦略マッピング
• 企業プロファイル・一覧表
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Myriad Genetics, Inc.
  • Beijing Genomics Institute（BGI）
  • QIAGEN
  • Perkin Elmer, Inc.
  • PacBio
  • Oxford Nanopore Technologies
  • PerkinElmer Inc
  • Macrogen, Inc

List of Tables

• TABLE 1. Cancer Incidence and Mortality, 2018
• TABLE 2. U.S. clinical Oncology NGS Market estimates & forecasts
• TABLE 3. U.S. clinical Oncology NGS Market estimates & forecasts, by technology, 2018 - 2030 (USD Million)
• TABLE 4. U.S. clinical oncology NGS market estimates & forecasts, by workflow, 2018 - 2030 (USD Million)
• TABLE 5. U.S. clinical oncology NGS market estimates & forecasts, by application, 2018 - 2030 (USD Million)
• TABLE 6. U.S. clinical oncology NGS market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market snapshot
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market trends & outlook
• Fig. 9 Market segmentation & scope
• Fig. 10 Penetration & growth prospect mapping for application, 2022
• Fig. 11 Penetration & growth prospect mapping for prominent industry players, 2022
• Fig. 12 Market driver relevance analysis (Current & future impact)
• Fig. 13 Cost per raw mega base (Mb) of DNA sequence (USD)
• Fig. 14 Cost per genome
• Fig. 15 Expected rise in expenditure for cancer treatment (USD Billion)
• Fig. 16 Number of new cancer cases in the World, 2022
• Fig. 17 Market restraint relevance analysis (Current & future impact)
• Fig. 18 SWOT Analysis, By Factor (political & legal, economic and technological)
• Fig. 19 Porter's Five Forces Analysis
• Fig. 20 Strategy framework
• Fig. 21 Participant categorization
• Fig. 22 U.S. clinical oncology NGS market: Technology outlook key takeaways
• Fig. 23 U.S. clinical oncology NGS market: Technology movement analysis
• Fig. 24 Whole genome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
• Fig. 25 Whole exome sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
• Fig. 26 Targeted sequencing and resequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
• Fig. 27 U.S. clinical oncology NGS market: Workflow outlook key takeaways
• Fig. 28 U.S. clinical oncology NGS market: Workflow movement analysis
• Fig. 29 NGS pre-sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
• Fig. 30 NGS sequencing for U.S. clinical oncology market, 2018 - 2030 (USD Million)
• Fig. 31 NGS data analysis for U.S. clinical oncology market, 2018 - 2030 (USD Million)
• Fig. 32 U.S. clinical oncology NGS market: Application outlook key takeaways
• Fig. 33 U.S. clinical oncology NGS market: Application movement analysis
• Fig. 34 Screening clinical oncology NGS market, 2018 - 2030 (USD Million)
• Fig. 35 Sporadic cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
• Fig. 36 Lifetime cancer risks for common cancers
• Fig. 37 Inherited cancer screening U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
• Fig. 38 Companion diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
• Fig. 39 Other diagnostics U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
• Fig. 40 U.S. clinical oncology NGS market, 2018 - 2030 (USD Million)
• Fig. 41 Key companies profiled

U.S. Clinical Oncology Next Generation Sequencing Market Growth & Trends:

The U.S. clinical oncology next generation sequencing market is expected to reach USD 500.4 million by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 15.1% from 2023 to 2030. The market is expected to increase at a significant rate during the forecast period from 2023 to 2030 owing to the increasing competition among the industry players, technological advances in the field and decreasing costs for genetic sequencing.

The increasing market competition and the launch of innovative solutions based on next generation sequencing in the oncology field are expected to fuel market growth over the forecast period. For instance, in February 2023, Exact Sciences Corp., a cancer screening and diagnostic testing company, introduced the therapy selection test -OncoExTra in the U.S. It is a next-generation sequencing-based genomic test to help in cancer care. It helps in understanding and characterizing cancer tumors. Moreover, to gain a competitive edge in the industry, companies are collaborating and focusing on advancing in the next generation sequencing. For instance, in January 2020, the two key players operating in the market, Illumina, Inc and F. Hoffmann-La Roche Ltd, signed a 15-year agreement to discover NGS's potential to transform cancer detection, diagnosis, risk prediction, treatment, and monitoring.

Moreover, various articles and studies are being published on the use of NGS in oncology and cancer treatments. For instance, in June 2023, the Lancet published an article on real-world outcomes and the usefulness of NGS testing in cancer patients. Furthermore, in June 2023, the American Society Of Clinical Oncology published a study on the clinical impact of NGS tests for managing advanced cancer in the U.S. Such studies help researchers and clinicians increase awareness and knowledge about the use of NGS for cancer treatments.

Furthermore, the growth of the clinical oncology next-generation sequencing market during the forecast period is expected to witness growth due to reduced sequencing costs. The costs of NGS can be reduced by increasing parallel sequencing and running multiple flow cells to increase sequencing capacity without raising the costs associated with it. These factors are anticipated to boost the market demand over the forecast period in the U.S.

U.S. Clinical Oncology Next Generation Sequencing Market Report Highlights:

• NGS sequencing accounted for the largest revenue share of 55.6% in 2022 based on the workflow segment. The dominance of the segments is due to the increasing number of cancer sequencing projects and technological advances in the field.
• Based on the technology, targeted sequencing & resequencing dominated the market with a revenue share of 72.9% in 2022. This can be attributed to the rising use of targeted panels and their efficiency in identifying cancer tumors.
• Based on the application, the screening segment dominated the U.S. clinical oncology NGS market with a revenue share of 80.6% in 2022, owing to the growing prevalence of cancer disorder across the country.
• Based on the end-use, the laboratories segment accounted for the largest share of 64.4% in the U.S. clinical oncology NGS market in 2022. This dominance of the segment is due to the rising research and development activities for cancer treatment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Information Procurement
• 1.2. Information or Data Analysis
• 1.3. Market Scope & Segment Definition
• 1.4. Market Model
  • 1.4.1. Market Study, By Company Market Share

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Reduction in costs for genetic sequencing
    • 3.2.1.2. Advances in the field of personalized medicine
    • 3.2.1.3. Increase in prevalence of cancer
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Lack of computational efficiency for data management
• 3.3. Industry Analysis Tools
  • 3.3.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.3.2. Porter's Five Forces Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Technology Estimates & Trend Analysis

• 4.1. U.S. clinical Oncology NGS Market: Technology Movement Analysis
• 4.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Technology (USD Million)
• 4.3. Whole Genome Sequencing
  • 4.3.1. Whole Genome Sequencing Market, 2018 - 2030 (USD Million)
• 4.4. Whole Exome Sequencing
  • 4.4.1. Whole Exome Sequencing Market, 2018 - 2030 (USD Million)
• 4.5. Targeted Sequencing & Resequencing
  • 4.5.1. Targeted Sequencing & Resequencing Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Workflow Estimates & Trend Analysis

• 5.1. U.S. clinical Oncology NGS Market: Workflow Movement Analysis
• 5.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By Workflow (USD Million)
• 5.3. 5 NGS Pre-Sequencing
  • 5.3.1. NGS Pre-Sequencing Market, 2018 - 2030 (USD Million)
• 5.4. NGS Sequencing
  • 5.4.1. NGS Sequencing Market, 2018 - 2030 (USD Million)
• 5.5. NGS Data Analysis
  • 5.5.1. NGS Data Analysis Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: Application Estimates & Trend Analysis

• 6.1. U.S. clinical Oncology NGS Market: Application Movement Analysis
• 6.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
• 6.3. Screening
  • 6.3.1. Screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.3.2. Sporadic Cancer
    • 6.3.2.1. Sporadic cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
  • 6.3.3. Inherited cancer
    • 6.3.3.1. Inherited cancer screening U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 6.4. Companion Diagnostics
  • 6.4.1. Companion diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 6.5. Other Diagnostics
  • 6.5.1. Other diagnostics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Clinical Oncology Next Generation Sequencing Market Categorization: End Use Estimates & Trend Analysis

• 7.1. U.S. clinical Oncology NGS Market: End Use Movement Analysis
• 7.2. U.S. clinical Oncology NGS Market Estimates & Forecast, By End-User (USD Million)
• 7.3. Hospitals
  • 7.3.1. Hospitals U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 7.4. Clinics
  • 7.4.1. Clinics U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)
• 7.5. Laboratories
  • 7.5.1. Laboratories U.S. clinical Oncology NGS Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company Categorization
• 8.2. Strategy Mapping
• 8.3. Company Profiles/Listing
  • 8.3.1. Illumina, Inc.
    • 8.3.1.1. Overview
    • 8.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.1.3. Product Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Thermo Fisher Scientific Inc.
    • 8.3.2.1. Overview
    • 8.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.2.3. Product Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. F. Hoffmann-La Roche Ltd
    • 8.3.3.1. Overview
    • 8.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.3.3. Product Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Agilent Technologies, Inc.
    • 8.3.4.1. Overview
    • 8.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.4.3. Product Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Myriad Genetics, Inc.
    • 8.3.5.1. Overview
    • 8.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.5.3. Product Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. Beijing Genomics Institute (BGI)
    • 8.3.6.1. Overview
    • 8.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.6.3. Product Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. QIAGEN
    • 8.3.7.1. Overview
    • 8.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.7.3. Product Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Perkin Elmer, Inc.
    • 8.3.8.1. Overview
    • 8.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.8.3. Product Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. PacBio
    • 8.3.9.1. Overview
    • 8.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.9.3. Product Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. Oxford Nanopore Technologies
    • 8.3.10.1. Overview
    • 8.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.10.3. Product Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. PerkinElmer Inc
    • 8.3.11.1. Overview
    • 8.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.11.3. Product Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Macrogen, Inc
    • 8.3.12.1. Overview
    • 8.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.3.12.3. Product Benchmarking
    • 8.3.12.4. Strategic Initiatives